Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
|Articles|October 2, 2008
Oncology NEWS International
- Oncology NEWS International Vol 17 No 10
- Volume 17
- Issue 10
Nobody puts cancer in a corner!
Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking.
Advertisement
Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking. Their “Virtual Stand Up” invites users to join the group’s FaceBook page, create a YouTube video, or send a real-time, short message called a “tweet.” A $1 donation nets a personalized “star” in SU2C’s virtual constellation.
Articles in this issue
about 18 years ago
Nanoparticles extend survival in pancreatic ca patientsabout 18 years ago
ACS spends big money to highlight healthcare system deficienciesabout 18 years ago
Visits to oncologists up, but profit per patient is on the declineabout 18 years ago
Report finds high rate of adoption of IMRTabout 18 years ago
Some HER2+ tumors prove resistant to trastuzumababout 18 years ago
NIH bankrolls molecular probes for targeted therapyabout 18 years ago
Oropharyngeal ca: IMRT spares salivary glandsabout 18 years ago
Fear of audit, lazy billing erodes profitsabout 18 years ago
Apoptosis inducer hits melanoma with double whammyabout 18 years ago
Triathlon for an MPD cureAdvertisement
Related to this article
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
5